Antihistamines H1 use on survival outcomes in esophageal squamous cell carcinoma patients undergoing concurrent chemoradiotherapy

Medicine and Dentistry

• Esophageal Squamous Cell Carcinoma 100%
• Chemoradiotherapy 100%
• H1 Antagonist 100%
• Overall Survival 30%
• Hazard Ratio 20%
• Survival Rate 10%
• Malignant Neoplasm 10%
• Dose Response 10%
• Proportional Hazards Model 10%
• Cancer Registry 10%
• Cohort Analysis 10%
• Allergic Response 10%
• Mitogen-Activated Protein Kinase 10%
• Immune System 10%

Pharmacology, Toxicology and Pharmaceutical Science

• Esophageal Squamous Cell Carcinoma 100%
• Chemoradiation Therapy 100%
• Histamine H1 Receptor Antagonist 100%
• Overall Survival 30%
• Defined Daily Dose 20%
• Survival Rate 10%
• Malignant Neoplasm 10%
• Cohort Study 10%
• Mitogen Activated Protein Kinase 10%
• Cancer Registry 10%
• Dose-Response Relationship 10%

Immunology and Microbiology

• Squamous Cell 100%
• Histamine H1 Receptor Antagonist 100%
• Overall Survival 30%
• Mitogen 10%
• Survival Rate 10%
• Dose Response 10%
• Hypersensitive Response 10%
• Immune System 10%